Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab biomarker and clinical response study in rheumatoid arthritis
2012-001760-30Phase 4Completed
- Sponsor
- GISEA
- Start
- Jul 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by GISEA. Primary endpoint: Disease Activity Score (DAS-44) at 12 months. Started Jul 2012; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2012-001760-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001760-30.